Pharmacogenomic considerations of the insertion/deletion gene polymorphism of the angiotensin I-converting enzyme and coronary artery disease

Curr Vasc Pharmacol. 2004 Jul;2(3):271-9. doi: 10.2174/1570161043385637.

Abstract

Gene polymorphisms of components of the renin-angiotensin system, angiotensinogen, angiotensin I-converting enzyme (ACE) and angiotensin II type 1 receptor (AT-1), have been considered to contribute to inherited predisposition towards coronary artery disease (CAD). The best analyzed is the insertion/deletion (I/D) gene polymorphism of the ACE gene. Several studies suggest that the ACE D allele is associated with the occurrence of CAD and myocardial infarction. Moreover, the I/D polymorphism of the ACE gene has been thought to be related to diverse responses to drugs. Modern gene technologies may therefore provide the information, which may help to identify disease-associated genes and determine the responsiveness to a given drug.

Publication types

  • Review

MeSH terms

  • Atherosclerosis / etiology
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / genetics*
  • Endothelium, Vascular / physiology
  • Humans
  • Peptidyl-Dipeptidase A / genetics*
  • Pharmacogenetics*
  • Polymorphism, Genetic*
  • Renin-Angiotensin System / physiology
  • Stroke / genetics

Substances

  • Peptidyl-Dipeptidase A